Please assess the completion status of the following clinical trial:

Trial Title: Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed CD for at least 6 months~* Clinically active disease (CDAI \>220 or Harvey-Bradshaw Index (HBI) \>6) or active by endoscopy.~* Biochemical evidence of disease activity (CRP \>5 and/or fecal calprotectin \>250)~Exclusion Criteria:~* Currently using EEN~* Condition that would preclude the use of EEN, such as Intestinal obstruction, perforation, toxic megacolon, massive gastrointestinal bleeding, abdominal abscess, or stricturing disease~* Previous intestinal resection with a remnant bowel of less than 180 cm~* Treatment with Prednisone in the last 30 days~* New start or change in dose of azathioprine, 6-mercaptopurine, cyclosporine, other immunosuppressant or biologics in the last 90 days. Doses of these medications must also remain unchanged for the duration of the study~* New start or change in dose of 5-aminosalicylic acid (ASA) in the last 30 days. 5ASA dose must remain unchanged for the duration of the study~* Use of Antibiotics or Probiotics in the last 30 days~* Pregnant or Lactating~* Any serious illness which could interfere with study procedures or results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard course CS with Regular Food (Type: ACTIVE_COMPARATOR): 40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
- Standard course CS with EEN (Type: EXPERIMENTAL): 40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
- Short course CS with EEN (Type: EXPERIMENTAL): 40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).